The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain reaction testing, whole genome sequencing, and wastewater sampling to screen for COVID-19 variants of concern. This contract is a follow-on to Ginkgo Bioworks' previous work supporting the CDC's pandemic response efforts. The company has substantial experience delivering biotechnology solutions to federal agencies, including the Department of Defense, Department of Energy, and U.S. Department of Agriculture.
Generated 9/29/24, 9:45 AM